Your trusted source for pharmaceutical industry knowledge, regulatory insights, clinical research updates, and healthcare innovation.
AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...
Biogen Inc. announced it has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash, plus one contingent value right (CVR) potentially worth up to $4...
Incyte Corporation announced executive leadership title changes effective March 25, 2026. Pablo J. Cagnoni is now President, Incyte and Global Head of Research and Development, replacing William J.
Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.
Exelixis, Inc. filed an 8-K on March 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The press release, furnished as Exhibit 99.
Ionis Pharmaceuticals announced significant changes to its Board of Directors. B. Lynne Parshall and Joseph H. Wender will retire at the end of their terms in June 2026.
Perrigo Company plc released its fourth-quarter earnings for the period ending December 31, 2025, via an 8-K filing with the SEC.
BeOne Medicines Ltd. (BGNE) filed an 8-K announcing its financial results for the fourth quarter and full year 2025. The press release, included as Exhibit 99.
Ionis Pharmaceuticals filed an 8-K on February 25, 2026, reporting its financial results for the quarter and fiscal year ended December 31, 2025.
Elanco Animal Health (ELAN) filed an 8-K on February 24, 2026, reporting its financial results for the full year and fiscal quarter ended December 31, 2025.